BPC-157

BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide derived from a protective protein fraction of human gastric juice ². It resists breakdown in gastric juice for more than 24 hours and is studied by oral, injectable, and topical routes in preclinical models ².

Researchers first characterized it in the early 1990s as an anti-ulcer "body protection compound" from the Sikiric laboratory at the University of Zagreb, under the investigational code PL 14736 ¹⁹. A Phase II ulcerative colitis program reported no side effects, but no randomized controlled trial has been published ⁶.

The most studied indications include tendon and ligament healing, muscle repair, gastrointestinal protection, and wound closure ¹². Results are strongest in animal models; human data are limited to fewer than 30 people across three uncontrolled pilot studies ³.

How BPC-157 works is still being mapped. The clearest direct interaction is with the FBXO22-BACH1 pathway. Inside cells, BPC-157 binds the adaptor protein FBXO22 through its proline residue at position 3, which keeps the transcription factor BACH1 from being broken down. Stabilized BACH1 then drives endothelial cell proliferation and tube formation, a basis for new blood vessel growth (angiogenesis) ¹³.

At the vascular level, BPC-157 signals through the Akt-eNOS pathway and vascular endothelial growth factor receptor 2 (VEGFR2), and activates the Src-Caveolin-1-eNOS pathway to influence blood vessel tone ⁶. Direct human tissue evidence shows that BPC-157 relaxes human internal mammary artery rings in an endothelium-dependent, nitric oxide (NO) mediated way that is largely blocked by the NOS inhibitor L-NAME ¹⁵.

Other reported mechanisms:

• Growth hormone sensitivity: upregulates growth hormone receptor in tendon fibroblasts, sensitizing them to growth hormone and activating JAK2 ¹⁸.
• Cell proliferation: activates ERK1/2 and its effectors c-Fos, c-Jun, and Egr-1, and increases VEGF-a in endothelial cells ¹⁷.
• Cytokine suppression: reduces TNF-α, IL-1β, and IL-6 in injured gastric tissue ⁷.
• KLF4: required effector for protection against radiation-induced liver injury ³⁰.
• Cholinergic activity: weak reversible acetylcholinesterase inhibition, orders of magnitude below clinical acetylcholinesterase drugs ¹⁴.

Emerging work frames BPC-157 as a bidirectional controller of angiogenesis and NO, promoting protective functions while suppressing excessive or damaging actions ²⁸.

Documented effects come mainly from rodent and in-vitro models. Human observations are uncontrolled pilot data.

• Tendon and ligament: rat Achilles transection with 10 mcg/kg/day intraperitoneally for 4 weeks improved histology and collagen organization, though maximum load to failure reached significance only for TB-500. Combined BPC-157 plus TB-500 gave no additive benefit ¹². Rat medial collateral ligament healing improved through 90 days with 10 mcg or 10 ng/kg daily ¹⁹.
• Muscle and junction: preclinical models report improved quadriceps muscle-to-bone reattachment and tendon-muscle junction healing ³⁵.
• Gut and GI: counteracts NSAID-induced gut injury and stabilizes intestinal barrier function in animal models ⁵⁵, and shows cytoprotective activity across occlusion and organoprotection models ²².
• Pain: in the rat incisional-pain model, 10-40 mcg/kg raised mechanical withdrawal threshold and reduced phase-1 formalin responses ²⁰.
• Human pilot observations: 10 of 12 interstitial cystitis patients had complete symptom resolution after one 10 mg intravesical injection ⁴; 7 of 12 knee pain patients reported more than 6 months of relief after intra-articular injection, though the series lacked controls and blinding ⁵; the IV pilot found no biomarker changes in 2 subjects ³.

No randomized controlled trial has been published, and human effect sizes remain unquantified ⁶. A 2025 systematic review included 36 publications, 35 preclinical and 1 clinical ⁵.

No approved or validated human dose exists. In studies, protocols span several routes and dose levels.

• Community injectable protocols: 250-500 mcg/day subcutaneous or intramuscular, often split into two daily injections, for 4-8 week cycles with equal off-periods.
• Rat benchmark: 10 mcg/kg/day intraperitoneally for 4 weeks in Achilles repair ¹²; 10 mcg or 10 ng/kg daily through 90 days in ligament models ¹⁹.
• Oral rat models: BPC-157 supplied in drinking water at 10 mcg/kg/day ²².
• Human pilots: intravenous 10 mg on day 1 and 20 mg on day 2 ³; single 10 mg intravesical procedure ⁴; non-standardized intra-articular knee injections ⁵.

Both 10 mcg/kg and 10 ng/kg are reproducibly active in rats, a 1,000-fold range, but no human dose-ranging data exist ¹². Human pilots used absolute doses far above community systemic protocols ³. Route comparisons are absent in humans ².

Duration in community research practice is typically 6-8 weeks on, 4 weeks off. No dependence, withdrawal, or rebound was reported in the human pilots ³. The timeline below shows one representative community pattern.

BPC-157 is distributed as lyophilized powder, typically in 5 mg vials, and no validated pharmaceutical-grade formulation exists ². In documented human pilots, preparations included compounded material and an intravenous formulation in normal saline ³.

For research handling, bacteriostatic water is the standard diluent rather than saline alone. Lyophilized powder is stored at -20°C for long-term stability or 2-8°C for shorter periods. Once reconstituted, the solution should be refrigerated at 2-8°C, protected from light, and discarded after 30 days. Analytical work shows the parent peptide is stable in urine for at least 4 days, while it degrades in serum within a week at 4-22°C ³³. BPC-157 resists degradation in human gastric juice for more than 24 hours ²².

Dilution volumes and resulting concentrations depend on the vial size and diluent volume. Use the calculator in this section for specific dilution math.

No formal human drug-drug interaction studies exist. BPC-157 is rapidly metabolized into amino acid fragments with a sub-30-minute plasma half-life, so pharmacokinetic induction or inhibition is unlikely ¹. Most documented interactions are pharmacodynamic.

• Nitric oxide pathway drugs: vasorelaxation in human artery rings is endothelium and NO dependent ¹⁵. In rat nephrotoxicity models, BPC-157 overcame both NOS blockade with L-NAME and NO overstimulation with L-arginine, suggesting context-dependent effects ⁴⁹.
• NSAIDs: BPC-157 counteracts NSAID-induced gastrointestinal injury and leaky gut in rats, including celecoxib-induced gastric lesions ⁵⁵.
• Anticoagulants and antiplatelets: BPC-157 does not directly affect coagulation assays and reduces both hemorrhage and thrombosis in rodent models ⁴⁶.
• Electrolyte-modifying drugs: counteracts furosemide-induced hypokalemia and magnesium overload in rats ⁵⁰.
• Growth hormone: BPC-157 upregulates growth hormone receptor in tendon fibroblasts and potentiates growth-hormone-stimulated proliferation ¹⁸.
• Anti-angiogenic cancer agents: evidence is unresolved. BPC-157 drives endothelial proliferation via FBXO22-BACH1, yet it inhibited melanoma cell growth and VEGF signaling in vitro ¹³.

Supplement interactions are largely mechanistic. L-arginine and citrulline overlap the same NO axis BPC-157 modulates ⁴⁹. Antiplatelet supplements are theoretically low risk for added bleeding because BPC-157 leaves standard coagulation measures unchanged ⁴⁶. Separate injectable administrations by 12-24 hours when stacking in research protocols.

No randomized trial defines an optimal BPC-157 cycle. Plasma half-life is under 30 minutes, but biological effects persist for hours to days, so continuous drug exposure is not required ¹. Community research protocols typically use 6-8 week courses followed by 4 weeks off, or shorter 2-4 week courses for local injury targeting. Human pilots used single or two-dose courses ³.

Cycle logic rests on several points.

• PK-PD disconnect: single doses produced prolonged functional recovery in rat spinal cord injury models ³⁸.
• Mechanistic argument: the FBXO22-BACH1 stabilization pathway supports time-limited rather than indefinite exposure ¹³.
• Safety conservatism: pro-angiogenic agents carry theoretical long-term vessel-growth concerns ¹¹.
• No tolerance data: no published preclinical work documents tolerance or tachyphylaxis, so cycling is precautionary rather than driven by receptor desensitization.

A symptom plateau or any new on-cycle symptom is a common reason in community practice to stop and reassess. Competitive athletes also need a conservative washout because a urinary metabolite remains detectable for at least 4 days after the parent peptide clears ³³.

Several combinations appear in research and community practice, but controlled data are sparse.

• BPC-157 + TB-500: in the sole controlled comparison, rat Achilles repair found no additive benefit over either peptide alone ¹².
• BPC-157 + growth hormone secretagogues: BPC-157 upregulates growth hormone receptor in tendon fibroblasts, and adding growth hormone potentiated fibroblast proliferation in vitro, suggesting theoretical synergy ¹⁸.
• BPC-157 + GHK-Cu: a common community healing stack based on complementary angiogenesis and extracellular matrix mechanisms, but no interaction data exist.
• BPC-157 + GLP-1 agonists: combination products are sold, but the FDA has determined BPC-157 unsafe for compounding ²¹. No efficacy or safety data support these combinations.

Because the only controlled combination study found no additive effect, research practice limits the number of regenerative peptides used at one time.

BPC-157 is not FDA-approved for any indication and has no EMA or other national marketing authorization ². The FDA has determined BPC-157 unsafe for use in compounded products ²¹. It is not scheduled under the U.S. Controlled Substances Act.

In sport, WADA placed BPC-157 on the Prohibited List under class S0 for non-approved substances in 2022 ¹⁰. One 2025 literature and patent review records that listing status has shifted and states it is not currently listed as banned, but S0 applies to substances without regulatory approval regardless of explicit listing ²³. Reviews in sports medicine describe standing antidoping restrictions ⁹.

Detection methods exist in urine and in dried and liquid blood matrices within anti-doping frameworks ²⁵. Athletes subject to testing should treat BPC-157 as prohibited and verify current list status. Distribution continues through unregulated direct-to-consumer channels, with documented risks of mislabeled or contaminated product ⁹.

The safety evidence base is thin. Across three uncontrolled human pilots with 26 total subjects, zero adverse events were reported ³. Preclinical toxicology did not achieve a lethal dose, and a Phase II ulcerative colitis program reported no side effects ²². No randomized controlled safety trial exists ⁶.

Community-reported effects not captured in trials include transient injection-site reactions, headache, light-headedness, nausea, and fatigue. These are typically self-limited and do not consistently recur.

The main real-world risk is supply-chain related: contamination, impurities, inaccurate dosing, and unverified vendors ⁹. Social media promotion rarely discloses risks; only 12.5% of analyzed posts mentioned adverse effects ⁹.

Theoretical concerns include:

• Angiogenesis and tumor biology: pro-angiogenic activity is mapped ¹³, but long-term human cancer risk is unstudied and contested ¹¹.
• Vasodilation: NO-mediated artery relaxation may add to low blood pressure with nitrates or antihypertensives ¹⁵.
• Growth hormone axis: GHR upregulation suggests a theoretical interaction with GH or IGF-1 compounds ¹⁸.
• Immunogenicity: generic peptide immunogenicity is a theoretical risk for any injectable peptide.

No human data exist for pregnancy, breastfeeding, pediatrics, or long-term exposure.